1.1Masking an activating ligand
An Fc-free antibody fragment covers the NKG2D-binding surface of MICA on graft cells. Blocking this interaction reduces the activating signal that contributes to NK cell degranulation.
Generated automatically. Not reviewed by a person. Not legal advice or an opinion.
Questions about how individual parts of claim 1 might be changed. A question may describe something different from what the claim language recites, or a version of it; no view is offered on which.
An Fc-free antibody fragment covers the NKG2D-binding surface of MICA on graft cells. Blocking this interaction reduces the activating signal that contributes to NK cell degranulation.
A soluble IL-15-binding protein sequesters free IL-15 before it associates with IL-15 receptor alpha on accessory cells. Reduced cytokine presentation limits IL-15-dependent priming of NK cell cytotoxicity.
A semipermeable hydrogel capsule encloses the graft cells and excludes intact NK cells. Oxygen, nutrients and small metabolic products diffuse through the capsule wall while the wall blocks direct cell contact.
Further arrangements of the same subject matter, described here as of the publication date at the foot of this page.
A diagnostic assay development laboratory uses an inhibitory KIR agonist as a reference reagent in an NK cell cytotoxicity assay. Paired wells contain fluorescently labeled target cells and NK cells that express the corresponding inhibitory KIR. One well contains the agonist and the other contains a matched carrier control. The difference in target cell death measures the assay's response to receptor-mediated inhibition.
A peptide-loaded HLA-C molecule from the C2 group replaces the antibody-derived binding domain in a reagent directed at inhibitory KIR2DL1. The HLA-C ectodomain is assembled with beta-2 microglobulin and a peptide that supports KIR2DL1 binding. A membrane-proximal tether anchors the complex to a supported lipid bilayer alongside an activating ligand. Contact with the bilayer brings inhibitory and activating receptors into the same interface, where KIR2DL1 engagement reduces NK cell degranulation.
Superparamagnetic beads replace living cells as the surface that displays an inhibitory KIR agonist. The bead coating immobilizes the agonist and a defined activating ligand so that each bead presents both signals to a contacting NK cell. Paired control beads carry the same activating ligand and a receptor-inert surface filler. A magnet removes the beads before flow cytometry measures NK cell surface CD107a.
Target cell mimics present the same inhibitory KIR agonist at nominal densities of 10, 100, and 1,000 molecules per square micrometer. Each surface carries the same density of activating ligand, and an agonist-free surface provides a baseline. Fluorescence calibration measures the actual agonist density on each surface. NK cell surface CD107a measured after 60 minutes provides a degranulation readout for the density series.
A perfused organoid chip holds a human tissue organoid beside a microfluidic channel that carries primary human NK cells. The organoid surface presents a membrane-tethered inhibitory KIR agonist, and the perfusate contains NK cells that express the matching receptor. Time-lapse fluorescence imaging records NK cell contact and tissue cell death. A parallel channel with matched organoids lacking the surface agonist provides a baseline under the same flow conditions.
A liquid-handling robot dispenses agonist concentrations, fluorescently labeled target cells, and receptor-matched NK cells into a multiwell plate. An automated microscope records target cell fluorescence and uptake of a membrane-impermeant death dye at fixed intervals. Image analysis counts dead target cells over time and corrects for spontaneous death using target-only wells. Software fits the concentration-response curve and reports the half-maximal inhibitory concentration with a confidence interval.
The graft cell surface displays peptide-loaded HLA-C with asparagine at residue 80, the defining residue of the C1 group. A peptide–HLA-C complex that binds KIR2DL3 recruits inhibitory signaling in NK cells that express the receptor.
A graft cell displays a single-chain antibody fragment on its membrane through a transmembrane anchor. The fragment binds an extracellular site on KIR2DL1 and clusters the receptor at the cell contact, where its intracellular inhibitory motifs recruit phosphatases that reduce NK cell activation.
Passages reproduced word for word from two earlier-published U.S. patent documents, placed beside the language of claim 1. No characterization is offered. Each passage is marked A or B for the document it comes from; ¶ numbers are the paragraph numbers in the USPTO’s published full text of that document.
In a preferred embodiment, the invention provides an antibody that binds both KIR2DL1 and KIR2DL2/3 human receptors, reverses inhibition of NK cell cytotoxicity mediated by these KIRs, and competes with DF200, 1-7F9, or NKVSF1 for binding to the KIR2DL1 human receptor, the KIR2DL2/3 human receptor, or both KIR2DL1 and KIR2DL2/3 human receptors.A · US 2018/0216069 A1 · ¶ 23
Tolerance of NK cells for self is mainly achieved by inhibitory killer cell immunoglobulin-like receptors (KIRs) and CD94/NKG2A-receptors on NK cells for HLA class I molecules on somatic cells [3]. Interactions of those inhibitory receptors with HLA class I molecules on autologous normal cells induce dominant negative signals which override activating signals and therefore prevent cytotoxic activity as defined by the “missing-self” hypothesis [5, 6].B · US 2021/0355446 A1 · ¶ 2
An empty cell means only that no passage was reproduced there.
The present invention relates to antibodies, antibody fragments, and derivatives thereof that cross-react with two or more inhibitory receptors present on the cell surface of NK cells and potentiate NK cell cytotoxicity in mammalian subjects or in a biological sample.A · US 2018/0216069 A1 · ¶ 2
Accordingly, effective NK cell-mediated therapy may require both a stimulation of these cells and a neutralization of inhibitory signals.A · US 2018/0216069 A1 · ¶ 6
The invention can be used as an “off the shelf” artificial feeder cell that can be readily designed to expand a NK cell or a NK subset of interest and also specifically expand NK cells modified with a chimeric antigen receptor (CAR).B · US 2021/0355446 A1 · ¶ 1
By genetically introducing or knockdown of candidate genes, the artificial feeder cell of the invention can be used to identify the stimulatory, co-stimulatory, and any other factors that mediate growth, expansion and cytotoxicity of a NK cell.B · US 2021/0355446 A1 · ¶ 1
patent.fyi, US 2026/0356939 A1, claim 1, first published 2026-11-20T08:53:13-05:00, https://patent.fyi/US20260356939/, SHA-256 7befebf52f1757634862afbd0e69b3d1a8b894200a9e8da5e44e9b6bf083e2c8